Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amgen’s Biosimilar Adalimumab First To EU Nod But No Launch

Executive Summary

Amgen’s biosimilar version of the anti-TNF adalimumab has become the first to receive an EU positive opinion but the company has no plans to launch the product this year.

Advertisement

Related Content

AbbVie's Gonzalez Calls Break-Up Proposal Rational, But Premature
Humira's Inevitable Decline: What's Waiting In The Wings?
CHMP’s January Recommendations Include Tofacitinib And Biosimilar Adalimumab
Blockbuster Competitors Figure Large Among Biosimilars Under Review in EU
Amgen/Allergan Target Lucrative Avastin Market With Another Biosimilar Filing
Coherus, In Ring As A Biosimilar Contender, Hopes To Smack Down Humira

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098129

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel